dopamine

Ligand id: 940

Name: dopamine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: dopamine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 3
Rotatable bonds 2
Topological polar surface area 66.48
Molecular weight 153.08
XLogP 0.57
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C. (2001)
Trace amines: identification of a family of mammalian G protein-coupled receptors.
Proc Natl Acad Sci U S A98: 8966-8971. [PMID:11459929]
2. Burris KD, Pacheco MA, Filtz TM, Kung MP, Kung HF, Molinoff PB. (1995)
Lack of discrimination by agonists for D2 and D3 dopamine receptors.
Neuropsychopharmacology12: 335-345. [PMID:7576010]
3. Engel K, Wang J. (2005)
Interaction of organic cations with a newly identified plasma membrane monoamine transporter.
Mol. Pharmacol.68 (5): 1397-407. [PMID:16099839]
4. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. (1996)
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
Proc. Natl. Acad. Sci. U.S.A.93 (10): 5166-71. [PMID:8643547]
5. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. (1994)
Expression and pharmacological characterization of the human D3 dopamine receptor.
J Pharmacol Exp Ther268: 417-426. [PMID:8301582]
6. Gründemann D, Liebich G, Kiefer N, Köster S, Schömig E. (1999)
Selective substrates for non-neuronal monoamine transporters.
Mol. Pharmacol.56 (1): 1-10. [PMID:10385678]
7. Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz JC, Sokoloff P. (1995)
A functional test identifies dopamine agonists selective for D3versus D2receptors.
Neuroreport6: 329-332. [PMID:7756621]
8. Schetz JA, Benjamin PS, Sibley DR. (2000)
Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology.
Mol Pharmacol57: 144-152. [PMID:10617689]
9. Shao W, Zhang SZ, Tang M, Zhang XH, Zhou Z, Yin YQ, Zhou QB, Huang YY, Liu YJ, Wawrousek E et al.. (2013)
Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin.
Nature494 (7435): 90-4. [PMID:23242137]
10. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. (1990)
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Nature347: 146-151. [PMID:1975644]
11. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB. (1991)
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Nature350: 614-619. [PMID:1826762]
12. Tiberi M, Caron MG. (1994)
High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype.
J. Biol. Chem.269: 27925-27931. [PMID:7525564]
13. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. (1991)
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.
Nature350: 610-614. [PMID:1840645]
14. Wang J. (2016)
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.
Clin. Pharmacol. Ther.100 (5): 489-499. [PMID:27506881]
15. Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z, Zhou R. (2015)
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome.
Cell160 (1-2): 62-73. [PMID:25594175]
16. Zhang Y, Jiang X, Qin C, Cuevas S, Jose PA, Armando I. (2016)
Dopamine D2 receptors' effects on renal inflammation are mediated by regulation of PP2A function.
Am. J. Physiol. Renal Physiol.310 (2): F128-34. [PMID:26290374]
17. Zhu HJ, Appel DI, Gründemann D, Markowitz JS. (2010)
Interaction of organic cation transporter 3 (SLC22A3) and amphetamine.
J. Neurochem.114 (1): 142-9. [PMID:20402963]